Cancer Immunology, Immunotherapy

, Volume 37, Issue 2, pp 105–111 | Cite as

Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro

  • Andreas Thanhäuser
  • Andreas Böhle
  • Hans-Dieter Flad
  • Martin Ernst
  • Taila Mattern
  • Artur J. Ulmer
Original Articles Bacillus Calmette-Guérin, Cellular Cytotoxicity, Bladder Cancer

Abstract

Cytotoxicity against two human bladder carcinoma cell lines (BT-A and BT-B) was investigated using human peripheral blood mononuclear cells (PBMC) stimulated with viable bacillus Calmette-Guérin (BCG) or sonicated BCG (s-BCG). We applied a cytotoxicity assay based on radioactive labelling of tumour cells by incorporation ofl[3H]methionine. The results were compared with the cytotoxicity exerted by lymphokine-activated killer (LAK) cells generated by interleukin-2 (IL-2) and interferon γ (IFNγ). BCG-stimulated PBMC showed a cytotoxic potential against BT-A and BT-B comparable to that of IFNγ-generated LAK cells, but this did not reach the level of IL-2-generated LAK cells. We termed these cytotoxic effectors BCG-activated killer (BAK) cells. In contrast to their cytotoxicity against bladder tumour cells. BAK cells did not differ from unstimulated PBMC in the killing of K562 cells. Only viable but not sonicated BCG was able to induce cytotoxicity against BT-A and BT-B. We could demonstrate the presence of the cytokines IFNγ, IL-2, tumour necrosis factor α (TNFα) and TNFß in the supernatants harvested during the generation of BAK cells. Monoclonal antibodies neutralizing IFNγ were able to inhibit BCG-mediated cytotoxicity, giving evidence of the involvement of IFNγ in the induction of BAK cells. Furthermore, we performed experiments to investigate the cytotoxic potential of distinct cell populations. The cells effective in BCG-activated killing of bladder tumour cells could be localized within the CD8+/CD56+ lymphocyte subset. CD4+ cells and macrophages did not exhibit cytolytic activity. Our findings imply that the activation by BCG of CD8+/CD56+ killer cells might be an important antitumoral mechanism during BCG therapy against superficial urothelial bladder cancer.

Key words

Bacillus Calmette-Guérin (BCG) Cellular cytotoxicity Bladder cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adams DO, Marino PA (1992) Evidence for a multistep mechanism of cytolysis by BCG-activated macrophages: the interrelationship between the capacity for cytolysis, target binding, and secretion of cytolytic factor. J Immunol 126/3: 981Google Scholar
  2. 2.
    Adolf GR, Lamche HR (1990) Highly sensitive enzyme immunoassay for human lymphotoxin (tumor necrosis factor-\) in serum. J Immunol Methods 130: 177PubMedGoogle Scholar
  3. 3.
    Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad H-D (1990) Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53PubMedGoogle Scholar
  4. 4.
    Böhle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad H-D (1990) Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 144: 59PubMedGoogle Scholar
  5. 5.
    Böhle A, Nowc Ch, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad H-D (1990) Detection of urinary TNF, IL-1 and IL-2 after local BCG immunotherapy for bladder carcinoma. Cytokine 2: 175PubMedGoogle Scholar
  6. 6.
    Brandt E, Ulmer AJ, Flad H-D (1986) Binding and characteristics of a monoclonal antibody against human IL-2 measurement. Lymphokine Res 5/1: 34Google Scholar
  7. 7.
    DeBoer EC, DeJong WHD, VanDerMeijden APM, Steerenberg PA, Witjes JA, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ (1991) Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother 33: 411PubMedGoogle Scholar
  8. 8.
    De Boer EC, De Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, De Groot ER, Van Der Meijden APM, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ (1992) Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother 34: 306PubMedGoogle Scholar
  9. 9.
    Ennen J, Ernst M, Flad H-D (1988) The effect of interleukin 2 on Fe-γ receptor function of human monocytes requires specific intercellular interaction. Immunobiology 179: 17Google Scholar
  10. 10.
    Feist W, Ulmer AJ, Musehold J, Brade H, Kusumoto S, Flad H-D (1989) Induction of tumor necrosis factor-α release by lipopolysaccharide partial structures. Immunobiology 179: 293PubMedGoogle Scholar
  11. 11.
    Findley HW, Nasr S, Afify Z, Hnath R, Waldrep K, Ragab AH (1990) Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro. Cancer Invest 8/5: 493Google Scholar
  12. 12.
    Fuchshuber PR, Lotzova E, Pollock RE (1991) Antitumor activity, growth, and phenotype of long term IL-2 cultures of human NK and T lymphocytes. Lymphokine Cytokine Res 10/1: 51Google Scholar
  13. 13.
    Fukiage T, Murakami H, Eura M, Ikawa T, Ishikawa T (1991) Killer cells induced by stimulation with allogeneic tumor cells and subsequent culture with recombinant interleukin 2. Cancer Immunol Immunother 33: 139PubMedGoogle Scholar
  14. 14.
    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon: lysis of natural-killer cell resistent fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823PubMedGoogle Scholar
  15. 15.
    Haff EO, Dresner SM, Kelley DR, Ratliff TL, Shapiro A, Catalona WJ (1985) Role of immunotherapy in the prevention of recurrence and invasion of urothelial bladder tumors: a review. World J Urol 3: 76Google Scholar
  16. 16.
    Harboe M, Closs O, Bjovatn B, Kronvall G, Axelsen NH (1977) Antibody response in rabbits to immunisation withMycobacterium leprae. Infect Immun 18: 792PubMedGoogle Scholar
  17. 17.
    Herr HW, Laudone VP, Whitmore WF (1987) An overview of intravesical therapy for superficial bladder tumors. J Urol 138: 1363PubMedGoogle Scholar
  18. 18.
    Ijzermans JNM, Marquet RL (1989) Interferon-γ a review. Immunobiology 179: 456PubMedGoogle Scholar
  19. 19.
    Jackson AM, Hawkyard SJ, Prescott S, Ritchie AWS, James K, Chisholm GD (1992) An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines. J Urol 147: 207PubMedGoogle Scholar
  20. 20.
    Kelly CD, Welte K, Murray HW (1987) Antigen-induced human interferon-γ production. Differential dependence on interleukin-2 and its receptor. J Immunol 139: 2325PubMedGoogle Scholar
  21. 21.
    Lange A, Flad H-D, Fetting R, Moniewska A, Jazwiec B, Ernst M, Ennen J (1990) Autologous regulation of rIL-2-activated natural killer cells: in: Schmidt (ed.): Natural killer cells: biology and clinical application. Karger, Basel, p. 197Google Scholar
  22. 22.
    Leibold W, Bridge S (1979)75Se-Release: a short and long term assay system for cellular cytotoxicity. Z Immunitaetsforsch 155: 287Google Scholar
  23. 23.
    Murphy M, Loudon R, Kobayashi M, Trinchieri G (1986) Gamma-interferon and lymphotoxin, released by activated T cells, synergize to inhibit granulocyte/monocyte colony formation. J Exp Med 168: 263Google Scholar
  24. 24.
    Nakamura K (1984) Monocyte-mediated cytotoxicity on bladder cancer cells in vitro and its implication in the treatment of bladder cancer patients with bacillus Calmette-Guérin. Keio J Med 33: 185PubMedGoogle Scholar
  25. 25.
    Ortaldo JR, Mason A, Overton R (1986) Lymphokine activated killer cells: analysis of progenitors and effectors. J Exp Med 164: 1193PubMedGoogle Scholar
  26. 26.
    Phillips JH, Lanier LL (1986) Dissection of the lymphokine-activated killer phenomenon: relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164: 814PubMedGoogle Scholar
  27. 27.
    Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1990) Radio-immunoassay detection of interferon-γ in urine after intravesical Evans BCG therapy. J Urol 144: 1248PubMedGoogle Scholar
  28. 28.
    Ratliff TI, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity J Urol 137: 155PubMedGoogle Scholar
  29. 29.
    Richter E, van der Bosch J, Böhle A, Flad H-D, Gerdes J (1991) The effect of bacillus Calmette-Guérin (BCG) on monocyte-mediated tumor cytotoxicity against bladder tumor cell lines (abstract). Immonobiol 183: 220Google Scholar
  30. 30.
    Rosenberg SA (1985) Lymphokine activated killer cells: a new approach to immunotherapy of cancer. JNCI 75: 595PubMedGoogle Scholar
  31. 31.
    Sone S, Lopez-Berestein G, Fidler IJ (1986) Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-γ and muramyl dipeptide derivatives. Cancer Immunol Immunother 21:93PubMedGoogle Scholar
  32. 32.
    Stötter H, Custer MC, Bolton ES, Guedez L, Lotze MT (1991) IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4. J Immunol 146: 150PubMedGoogle Scholar
  33. 33.
    Toledano M, Mathiot C, Michon J, Andreu G, Lando D, Brandely M, Fridman WH (1989) Interferon-γ (IFN-γ) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity. IFN-γ-induced suppressive activity. Cancer Immunol Immunother 30: 57PubMedGoogle Scholar
  34. 34.
    Ulmer AJ, Scholz W, Ernst M, Brandt E, Flad H-D (1984) Isolation and subfractionation of human peripheral blood mononuclear cells (PBMC) by density gradient centrifugation on Percoll. Immunobiology 116: 238Google Scholar
  35. 35.
    Van der Bosch J, Rüller S, Horn D, Schumann R, Schlaak M (1990) Density-dependent tumor cell death and reversible cell cycle arrest: mutually exclusive modes of monocyte-mediated growth control. Exp Cell Res 187: 185PubMedGoogle Scholar
  36. 36.
    Wang M-H, Flad H-D, Böhle A, Chen Y-Q, Ulmer AJ (1991) Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines. Immunol Lett 27: 191PubMedGoogle Scholar
  37. 37.
    Weidmann E, Bergmann L, Hechler P, Mitrou PS (1991) Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer with interleukin-2. Cancer Immunol Immunother 33: 398PubMedGoogle Scholar
  38. 38.
    Whiteside TL, Hro DS, Takagi S, Johnson JT, Iwatsuki S, Herberman RB (1988) Cytolytic antitumor effector cells in long-term cultures of human tumor infiltrating lymphocytes in recombinant interleukin-2. Cancer Immunol Immunother 26: 1PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Andreas Thanhäuser
    • 1
  • Andreas Böhle
    • 2
  • Hans-Dieter Flad
    • 1
  • Martin Ernst
    • 1
  • Taila Mattern
    • 1
  • Artur J. Ulmer
    • 1
  1. 1.Department of Immunology and Cell BiologyForschungsinstitut BorstelBorstelGermany
  2. 2.Department of UrologyMedical University of LübeckLübeckGermany

Personalised recommendations